Serum CA125 levels in the context of ProMisE molecular classification provides pre-operative prognostic information that can direct endometrial cancer management
CA125 levels are associated with molecular subtype, stage>I disease, and SEOC/CAM. CA125 remains a useful clinical tool in the triage of EC in the era of molecular classification.
Authors
- Derek S. Chiu (ORCID: https://orcid.org/0000-0002-7591-4881)
- Amy Lum (ORCID: https://orcid.org/0000-0002-9236-2492)
- C. Blake Gilks (ORCID: https://orcid.org/0000-0001-7889-8250)
- Jessica N. McAlpine (ORCID: https://orcid.org/0000-0001-6003-485X)
- Amy Jamieson (ORCID: https://orcid.org/0000-0002-3210-9102)
- Andrea Neilson
- Aline Talhouk (ORCID: https://orcid.org/0000-0001-7760-410X)
- David G. Huntsman (ORCID: https://orcid.org/0000-0003-4934-3322)
- Samuel Leung
- Stefan Kommoss
Institutions
- University of British Columbia (CA)
- University Children's Hospital Tübingen (DE)
Publication Details
- Journal
- Gynecologic Oncology
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1016/j.ygyno.2024.12.010
- Citations
- 4
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.33
Funders
- VGH and UBC Hospital Foundation
- Michael Smith Health Research BC
- Canadian Cancer Society
- Canada Research Chairs
- Vancouver Coastal Health Research Institute
- BC Cancer Foundation